Norovirus infections are the leading cause of non-bacterial gastroenteritis and result in about 21 million new cases and $2 billion in costs per year in the United States. Existing diagnostics have limited feasibility for point-of-care applications, so there is a clear need for more reliable, rapid, and simple-to-use diagnostic tools in order to contain outbreaks and prevent inappropriate treatments. In this study, a combination of phage display technology, deep sequencing and computational analysis was used to identify 12-mer peptides with specific binding to norovirus genotype GI.1 virus-like particles (VLPs). After biopanning, phage populations were sequenced and analyzed to identify a consensus peptide motif-YRSWXP. Two 12-mer peptides containing this sequence, NV-O-R5-3 and NV-O-R5-6, were further characterized to evaluate the motif's functional ability to detect VLPs and virus. Results indicated that these peptides effectively detect GI.1 VLPs in solidphase peptide arrays, ELISAs and dot blots. Further, their specificity for the S-domain of the major capsid protein enables them to detect a wide range of GI and GII norovirus genotypes. Both peptides were able to detect virus in norovirus-positive clinical stool samples. Overall, the work reported here demonstrates the application of phage display coupled with next generation sequencing and computational analysis to uncover peptides with specific binding ability to a target protein for diagnostic applications. Further, the reagents characterized here can be integrated into existing diagnostic formats to detect clinically relevant genotypes of norovirus in stool.
Introduction
Norovirus infection is the leading cause of foodborne illness, resulting in over 267 million new cases and 200 000 deaths per year around the globe (Donaldson et al., 2008; Patel et al., 2008) . Known as the 'winter vomiting disease', symptoms commonly include vomiting, nausea and diarrhea with the number of outbreaks peaking during the winter months (Clarke et al., 1972) . Given the low infectious dose that averages approximately 1320 virions and can be as low as 400 virions , infections spread rapidly in areas of close person-to-person contact with 70% of outbreaks occurring in longterm care facilities and the remainder in places such as schools, hospitals, restaurants and cruise ships (Wikswo et al., 2015) .
Part of the Caliciviridae family of positive-sense RNA viruses, norovirus contains a genome of~7.6 kb in length that includes three open reading frames-ORF1, ORF2, ORF3. The icosahedral capsid that encases the genome is composed of 90 dimers of the major capsid protein, viral protein 1 (VP1), which is encoded by ORF2 (Hutson et al., 2004; Muhaxhiri et al., 2013) . The structure of VP1 includes two subdomains-the highly conserved inner shell (S)-domain, and the more variable protruding (P)-domain. Based on the amino acid sequences of VP1, noroviruses are classified into six genogroups (GI-GVI), wherein GI and GII infect humans, and are further organized into genotypes that encompass various strains and variants (Hutson et al., 2004; Glass et al., 2009; Kroneman et al., 2013) . The first norovirus was identified in 1972 following a school outbreak in Norwalk, Ohio, and has become the prototypical, most widely studied norovirus with genotype GI.1 (Kapikian et al., 1972) .
Although infections are self-limiting and resolve within 24-48 h in healthy individuals, the spread of norovirus outbreaks can result in major societal repercussions and further complications among highrisk populations. Among healthy populations, outbreaks result in large financial costs (estimated $2 billion per year in the United States (Hoffmann et al., 2012) ) and lost productivity. Immunocompromised, elderly and pediatric patients under 5 years of age may experience more severe and chronic infection, particularly in the event of administration of inappropriate treatments that could also contribute to antibiotic resistance (Ye et al., 2015) . Since there is no treatment currently available for infection besides rehydration, rapid and accurate diagnosis is essential in order to prevent the spread of outbreaks by initiating decontamination procedures, and to prevent the use of inappropriate treatments such as antibiotics or immunosuppressant drugs that may follow the lack of proper diagnoses. Thus, improved diagnostics that can provide rapid results for individual patients in clinics where polymerase chain reaction (PCR) or experienced technicians may not be available would help to alleviate these issues.
Current diagnostics, including reverse transcriptase (RT)-PCR and enzyme-linked immunoassays (ELISA), present limitations that preclude their use for individual patient diagnosis or for timely results in rural and developing geographic regions. While RT-PCR can detect 90% of human-infecting strains using multiple primer sets, the equipment and expertize required to perform tests are typically found only in large medical facilities and are thus inaccessible and prohibitively expensive to use at other locations (Atmar and Estes, 2006) . Enzyme immunoassays, in contrast, require less complex equipment, but still take several hours and technical skill to produce a result. They also have limited sensitivity, resulting in Food and Drug Administration approval for use only during outbreaks or preliminary screening to be confirmed by RT-PCR (Ambert-Balay and Pothier, 2013) . Overall, the current status of norovirus diagnostics demands a rapid, accurate and easy-to-use tool in order to diagnose individual patients, and to detect and contain outbreaks more quickly.
Phages have long been used as diagnostic reagents to detect host bacterium and have progressed more recently via synthetic biology to present diagnostic tools for numerous target pathogens (Schofield et al., 2012; Lu et al., 2013) . For instance, phage selection has been used successfully to identify peptides that show promise for use in applications for diagnosing transmissible gastroenteritis virus (Zou et al., 2013) , equine infectious anemia (Santos et al., 2012) and other viral infections (Miller et al., 2014; Wang et al., 2015) . Advantages of using phage reagents over antibodies in point-of-care diagnostics include the extremely low cost of production and the connection between genotype and phenotype in phage that enables easy identification of lead reagents by sequencing after highthroughput screening (Hamzeh-Mivehroud et al., 2013) . Previous studies by our group have identified phage-displayed peptides and single-chain antibodies that bind VP1 of norovirus (Rogers et al., 2013; Huang et al., 2014) . Specifically, the phage-displayed peptide previously characterized, called NV-N-R5-1, was found to bind GI.1 virus-like particles (VLPs) through the highly variable P-domain of VP1 (Rogers et al., 2013) . These studies provided proof-of-concept that phages are useful for binding norovirus and can achieve sensitivities at least equal to those demonstrated by antibodies used in current immunoassay diagnostics. Building upon this work, phage-based reagents that demonstrate specificity for additional genotypes with high sensitivity and utility in diagnostically useful formats would provide additional support to improving clinical diagnostics for norovirus.
In order to facilitate the discovery of the optimal binding reagents based on randomized phage-displayed peptide libraries, computational methods have been developed to identify peptide motifs across entire populations of screened peptides. Examples of custom bioinformatics tools include MatLab-based software developed by Derda and colleagues that evaluates Illumina DNA sequencing results (Matochko et al., 2012) , the MUltiple Specificity Identifier (MUSI) developed by Kim et al. (2012) , and Multiple Em Motif Elicitation (MEME) (Ryvkin et al., 2012) . Rather than picking individual clones to identify leads, these computational methods facilitate rapid discovery of optimal binders present in a population of thousands of clones via consensus sequences, thus providing an advantage over traditional phage display methodologies. Unfortunately, despite progress made by many different groups to develop computational analysis software for peptide motif discovery, studies seeking to identify consensus peptide binders for novel protein targets still tend to require custom software for analysis. Nonetheless, the powerful combination of phage display technology and high-throughput sequencing, termed 'deep panning' by Ryvkin et al. (2012) , has been used effectively to identify specific target-binding peptides. In one example, Rentero Rebollo et al. (2014) developed custom MatLab scripts to elicit peptide motifs that bind four different protein targets based on Ion Torrent sequencing of screened peptide-phages. Studies such as this demonstrate the powerful potential of deep panning applications for rapidly identifying consensus peptides for any pathogen-related protein of interest.
In this paper, we combine phage display technology with translational bioinformatics to identify and characterize a consensus peptide sequence that binds norovirus. Starting with a library of randomized phage-displayed 12-mer peptides, we selected for binders with Norwalk virus (GI.1) (NV VLPs) and deep sequenced the resulting population of phages to identify a consensus sequence through computational analysis. Individual peptides containing the consensus sequence demonstrated effective detection of several GI and GII genotypes and GI.1 virus in clinical stool samples. The consensus sequence and binding properties of the individual clones identified here are different than the NV-N-R5-1 peptide previously identified (Rogers et al., 2013) and thereby broadens the range of available reagents for the detection of Norovirus.
Materials and methods

Biopanning phage-displayed peptide libraries
Recombinant VLPs were generated and characterized previously through the use of a baculovirus expression system (Kou et al., 2015a) . Specifically, VP1 and VP2 capsid proteins were expressed in Sf9 insect cells, and purified through a cesium chloride gradient (Jiang et al., 1992) . The norovirus strains used to represent the genotypes indicated in this study were defined previously by our group (Kou et al., 2015b) . Prior to biopanning, NV VLPs were immobilized on immunotubes (Nunc) at 5-μg/mL in 1 mL of phosphatebuffered saline (PBS) by incubating overnight at 4°C. The next morning, tubes coated with VLP were washed twice with 1 mL of PBS and blocked for 2 h with 1 mL of 10% nonfat dry milk in PBS (MPBS) gently rocking at room temperature, followed by three washes with 1-mL PBS. In the first round of biopanning, tubes were incubated with 10 11 pfu from the phage display 12-mer peptide library kit from New England BioLabs (prod #E8110S) in 1 mL of 1% MPBS for 2 h gently rocking at room temperature. In subsequent rounds of biopanning, tubes were incubated with 10 11 pfu from the amplified population of phages eluted from the most recent round of biopanning. Incubation was followed by 10 washes with 1-mL PBS-T (0.05% Tween-20 in PBS) to remove non-binding phages. Finally, phages that interacted with NV VLPs were eluted with 1 mL of elution buffer (0.2 M glycine-HCl, 1-mg/mL bovine serum albumin [BSA], pH 2.2). The eluate was transferred to a microcentrifuge tube after 10 min of incubation and neutralized with 150 μL of neutralization buffer (1 M Tris, pH 9.2).
Phage titration and amplification
Following each round of biopanning, the number of eluted phages was determined by 10-to 1000-fold titrations and plaque growth was evaluated as described previously (Rogers et al., 2013) . The phage population was then amplified by infecting 30 mL of mid-logphase Escherichia coli TG1 cells with 250 μL of the eluted phages. Infected cells were incubated for 20-24 h shaking at 30°C and then centrifuged for 10 min at 3000 × g to remove cells. Phages were precipitated from the supernatant by incubating with 6 mL of 20% polyethylene glycol, 2.5 M NaCl overnight at 4°C followed by centrifugation for 30 min at 3000 × g. The supernatant was discarded and phage pellets were resuspended with PBS and titrated to determine the phage concentration.
Phage DNA preparation and sequencing
The sequences of individual phages were determined by picking single plaques from titer plates to use as template for PCR amplification of the gene III region of the phage genome that expresses the displayed peptide. The primers used were M13KE Top, GCTGATAAACCGATACAATTAAAGGC, and M13KE-1396 Bot, GGCCTTTAACTCCCTGCAAGCCTCAG. PCR products were purified and DNA sequencing was performed to determine the identity of the phage-displayed peptide (Lone Star Labs, Houston, TX). For high-throughput sequencing, DNA was prepared directly from the phage populations that were eluted during the third and fourth rounds of biopanning. PCR amplification of the region expressing the displayed peptide was performed on 5 μL of each phage population and barcodes were included to distinguish the phage populations from separate rounds of biopanning. PCR products were purified and 454 ultrahigh-throughput sequencing was performed on a 454 GS FLX Titanium Series Amplicon Sequencing Platform at the Human Genome Sequencing Center at Baylor College of Medicine (Houston, TX).
Computational analysis of deep sequencing results
Custom scripts were written in Perl or Python to process and analyze the deep sequencing results. Results from 454 sequencing were initially processed using Perl scripts in order to sort sequences according to their barcodes, extract the nucleotides that encoded the displayed peptides and translate them into amino acid sequences. The output from this process returned an array with three columns including the 12-mer amino acid sequence, the number of replicate sequences that returned the same sequence and a unique read number. Next, this file was used as the input for the python script, 'main.py' in order to identify a consensus peptide motif based on the unique sequences expressed throughout the selected phage population. In order, main.py performs sequence analysis by calling upon functions that break the 12-mer peptide sequences into smaller peptide fragments, eliminate fragments that lack a minimum identity with other fragments, and align the remaining fragments using MAFFT software ( Fig. 2A) (Katoh et al., 2002; Katoh and Standley, 2013) . A list of the scripts used for these analysis steps and descriptions of their functions can be found in Table S1 .
The scripts called by main.py were written to allow the user to customize their analysis by specifying the length of the sequence fragments produced and the stringency by which the fragments are filtered by adjusting the minimum number of amino acids required to be in common to produce a fragment 'match'. In this study, peptides were broken into 6-mer fragments starting from the N-terminus and sliding down to the C-terminus such that every 12-mer was broken into seven daughter fragments. Fragments were then compared pairwise, except for fragments derived from the same parent 12-mer, and discarded if they did not produce a 'match' by sharing the specified number of amino acids in common with at least one other fragment in the population. The number of amino acids required for a match ranged from three to five (Fig. 2B ). The group of fragments that remained were saved in a list designated as 'Matching', while the discarded fragments were 'Non-Matching'. The set of 'Matching' 6-mer fragments was next aligned using MAFFT software, which stacks the population of peptides such that matching amino acids lineup in vertical columns. The software shifts the peptides left or right in relation to one another in order to lineup amino acids that match in different positions of the peptides. Thus, the columnar width of a final completed alignment varies depending on the amount of shifting required to lineup the most closely matching amino acids. Using the final peptide alignment produced by MAFFT, a sequence logo was generated using the WebLogo application in order to visualize a representative consensus motif (Crooks et al., 2004) . The x-axis of the WebLogo represents the number of columns that appeared in the final peptide alignment produced by MAFFT.
ELISA detection of VLPs with phage-displayed peptides
96-well polystyrene plates were coated with 100 μL of PBS containing dilutions of VLPs varying from 5 μg/mL down to 0.0025 μg/mL or with no VLPs (0 ng/well) overnight at 4°C. Wells were washed twice with 100-μL PBS and blocked with 10% MPBS for 2 h gently rocking at room temperature. After three more washes with PBS, 5 × 10 10 pfu of phage in 1% MPBS was added to each well and incubated for 2 h rocking at room temperature. Following six washes with 0.05% Tween-20 in PBS (PBS-T), horseradish peroxidase (HRP)-conjugated M13 antibody (Pharmacia Biotech) diluted 1:5000 in 1% MPBS was added and incubated 45 min rocking at room temperature. After six washes with PBS-T, HRP was developed with HRP substrate, 3,3,5′-tetramethylbenzidine (TMB, Kirkegaard and Perry Laboratories [KPL]) for 10 min, and stopped with 1 M H 3 PO 4 (KPL). Absorbance was measured to determine the optical density (OD) at 450 nm using a plate reader (Tecan Infinite M300 Pro). The limit of detection (LOD) was defined as the lowest concentration of VLPs that produced a statistically significant binding signal based on a t-test between the replicates at a given concentration and those at zero ng/well of VLPs where P < 0.05.
SPOT peptide array synthesis and development
Peptides were synthesized on a cellulose membrane using an automated MultiPep RS robot (Intavis, Bergisch Gladbach, Germany) using SPOT synthesis, developed and described previously by Ronald Frank and co-workers (Frank, 2002) . For membrane development, the SPOT array was washed with methanol for 10 min, then twice with PBS-T for 10 min and blocked with SuperBlock Blocking Buffer in PBS (Thermo Scientific, product #37515) overnight at 4°C. The next morning, the membrane was washed three times with wash buffer (1% BSA in PBS-T) for 10 min, and then incubated with 1-μg/mL NV VLP diluted in wash buffer shaking at room temperature for 2 h. After another three 10 min washes, the membrane was incubated with anti-NV polyclonal antibody (1:2000) in wash buffer for 45 min. Following another three washes, secondary antibody (anti-rabbit-HRP, 1:2500) was added for 45 min. Finally, HRP was developed with either SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, product #34080) or TrueBlue™ Peroxidase Substrate (KPL, product #50-78-02) to detect signal.
Dot blots
Norovirus VLPs were diluted to the appropriate concentrations and seeded directly onto Whatman nitrocellulose membranes as 1-μL dots in duplicate per dilution. VLPs were diluted in either PBS or 10% norovirus-negative stool suspension, and stool samples positive for norovirus were diluted in PBS. Dots were allowed to air dry completely at room temperature, then blocked with 10% MPBS for 2 h. After three 5-min washes with PBS-T, phages were added to the membranes at 5 × 10 10 pfu per mL in 1% MPBS and incubated for 30 min gently shaking at room temperature. For a positive control, rabbit anti-NV polyclonal antibody diluted 1:3000 in 1% MPBS was used in place of phage. Following three more washes with PBS-T, membranes were incubated with anti-M13 HRP-conjugated antibody (Pharmacia Biotech, product #GE27-9421-01) diluted to 1:5000 in 1% MPBS for 30 min. For the positive control, polyclonal antibody was detected using a 1:3000 dilution of anti-rabbit HRPconjugated as the secondary antibody. Membranes were washed three times again and developed with TrueBlue™ for 10 min. Photographs of the membranes were taken for visualization.
Results
Enrichment of GI.1-binding phage-displayed peptides
The goal of this work was to identify and characterize a consensus peptide motif that could bind to the norovirus VP1 capsid protein and thus detect the presence of norovirus. To begin, GI.1 NV VLPs were immobilized to an immunotube and biopanning was performed with a phage-displayed, randomized 12-amino acid peptide library (Materials and methods). Phage populations eluted after serial rounds of biopanning were evaluated for their abilities to bind GI.1 VLPs. The binding signals increased in the later rounds of selection as compared to earlier rounds as shown in an ELISA (Fig. 1A) , indicating that the biopanning selection was successful in enriching for phages that bind to immobilized GI.1 VLPs. As expected, the negative control phage, which expresses the M13KE vector without a peptide inserted into the cloning site (Noren and Noren, 2001) , showed insignificant background binding signal. The signals produced by each population for binding BSA were subtracted from GI.1-binding signals in order to remove background. To assess the total population of peptide sequences eluted from biopanning and subsequently identify a consensus binding peptide sequence, deep sequencing was performed on the phage populations from the final two rounds of biopanning. Specifically, a DNA region that includes the nucleotide sequence that encodes the displayed peptide was amplified from the phage populations eluted after rounds three and four, purified and sequenced by the 454 DNA sequencing procedure. The results returned 15 767 and 5475 total sequence reads for rounds three and four, respectively. Custom computer programs were used to extract the sequences encoding the 12-mer peptides from the FASTQ sequencing results and to translate the codons into their corresponding amino acids.
In order to evaluate the proportion of the phage populations covered by individual, unique peptide sequences, the frequencies of each unique peptide were plotted as a fraction of the total sequence reads (Fig. 1C) . Removing replicate peptide sequences from the original lists of peptides appearing in each of the biopanning round three and four phage populations resulted in 5386 and 761 unique sequences, respectively (Fig. 1B) . The most frequent peptides account for the largest individual proportions of the populations and appear at the bottom of the bar graph, where IQYRSWIPFSYP (in blue) was the most frequent peptide found in each population. Less frequent peptides were pooled for ease of visualization and appear at the top of the bar graph. Peptides with 11 to 20 replicates in the population are in the group named 'freq 11-20'; peptides with 2 to 10 replicates are in group 'freq 2-10'; and peptides appearing only once in the population are called 'singletons' and are shown at the top of the graphs since they were the least frequent. As biopanning selection progressed from round three to four, the most frequent peptides (i.e. shown in blue, red, green, purple and orange) increase in their fractional frequencies, while the fractions containing groups of less frequent peptides are reduced as weak or nonbinding phage-displayed peptides disappear from the population. The expansion of high frequency peptides combined with the increased binding signal via ELISA provides evidence that the biopanning selection effectively enriched for phages displaying peptides that were the most capable of binding GI.1 VLP compared to other peptides in the original library.
Deep sequencing analysis reveals consensus peptide motif
In order to identify a consensus peptide motif resulting from biopanning of the original phage display library, computational analysis was performed to evaluate all of the peptides appearing in the population from the fourth round of biopanning. For a preliminary evaluation of the amino acids enriched through biopanning, the occurrence of each amino acid was counted in the naïve phage library population and the populations from rounds three and four using the 'countAAfreqFromArray' script (Table S1 ). A graph of the amino acid frequencies revealed enrichment of P, R, S, W and Y in the selected populations compared to the naïve library, suggesting that these amino acids were involved in binding GI.1 VLP (Fig. S1 ). While this result did not suggest an order in which these amino acids might appear, it established expectations for what components should appear in a consensus peptide motif based on amino acid frequencies alone.
For deeper evaluation of the round-four phage population to find a consensus peptide, Fig. 2A shows a schematic of the custom analysis performed, as described in the methods. When the minimum number of amino acids shared between peptide fragments during the filtering step increased stepwise from three to four to five, the number of remaining fragments in the 'Matching' group decreased from 98.5% to 13.3% to 2.7% of the total fragments (Fig. 2B) . The sequence logos produced by the alignment of sequences in each 'Matching' group also showed the gradual emergence of a strong consensus motif-YRSWXP-that represents the most dominant arrangement of amino acids that appears across the population of peptides that resulted from biopanning (Fig. 2C) . The shorter width of the peptide alignment in the last run, represented by the shorter x-axis compared to the first two runs, further indicates the prevalence of these amino acids across the 145 fragments in that 'Matching' group since the software did not need to shift the peptides as much to fit the peptides into alignment.
Validation of specific peptide binding to VLPs
To evaluate the functional capacity of the consensus motif to bind norovirus, several functional assays were performed with and without the context of the phage (Figs. 3-5) . Two of the most frequent peptides in the phage populations-IQYRSWIPFSYP and LDYRSWAPYATScontain the entire consensus motif, and were named NV-O-R5-6 and NV-O-R5-3, respectively (Fig. 3A) . It is noteworthy that the previously identified and characterized NV-N-R5-1 peptide, while containing the 'SW' amino acids, is not a good match to the 'YRSWXP' consensus sequence (Fig. 3A) .
The NV-O-R5-6 and NV-O-R5-3 peptides that contain the consensus were previously identified by our group through selection of single phage clones and were briefly characterized for their abilities to bind NV VLPs via ELISA (Rogers et al., 2013) . While it was found that they could indeed detect immobilized NV VLPs, they could not detect antibody-captured VLPs. When each of these peptides was synthesized on a solid-phase cellulose membrane using the SPOT synthesis method (Frank, 2002) and probed with GI.1 VLPs, they both showed strong binding signals (Fig. 3B ). This result confirms that these peptides are also able to bind VLPs outside of the context of the phage. Similarly, the third most frequent peptide, YRSFDPWYPPVH, which contains a slight variation of the consensus peptide motif that starts at residue one of the peptide rather than at the third amino acid, produced a significant signal in this format as well. Negative control peptides, T7 and Strep-Tag II, showed no background signal with GI.1 VLPs on the same array.
Peptides containing the consensus sequence bind GI and GII VLPs
Next, we sought to determine the range of specificity of the 'YRSWXP' peptides for binding different norovirus genotypes, and to compare their specificity to that of phage-displayed peptide NV-N-R5-1, which we had previously characterized solely for its ability to bind GI.1. To do so, the two 'YRSWXP' peptides, NV-N-R5-1 and M13KE phages were each evaluated for their abilities to bind a panel of GI and GII VLPs immobilized directly in separate ELISA wells (Fig. 3C) . Results are reported as the ratio of the OD signals produced by each peptide-displaying phage compared to the M13KE phage, which does not display a peptide.
All four phages tested, including M13KE, showed negligible binding signal to BSA, which represents a control for non-specific binding of the phages to an unrelated protein. Further, M13KE phage showed similarly low background signals against all of the VLPs tested as a negative control for binding caused by the phage proteins. Interestingly, both NV-O-R5-3 and NV-O-R5-6 phage-displayed peptides showed statistically significant binding signals for all nine of the GI and GII genotypes tested (Fig. 3C) . In contrast, NV-N-R5-1 showed significant binding only to GI.1 VLPs, indicating strong specificity to just one genotype. This result reveals an advantage of the two new peptides given their abilities to detect norovirus genotypes that are unrecognized by NV-N-R5-1. More surprisingly, the two new peptides showed particularly strong binding signals with GII.12 and GII.17 compared to GI.1, where the signals against GII.17 matched or exceeded the intensity of those from NV-N-R5-1 detecting GI.1. These results demonstrate unique characteristics of NV-O-R5-3 and NV-O-R5-6 based on their specificities for norovirus genotypes to which few reagents bind so strongly. Further, these properties reveal an advantage of the two new peptides given their abilities to detect norovirus genotypes that are unrecognized by NV-N-R5-1. Although the amino acid sequence of NV-N-R5-1 (shown in Fig. 3A) contains an 'SW', which is a portion of the consensus motif, the notably different binding properties demonstrated by this peptide further indicate that it is not a match to the 'YRSWXP' motif.
Looking more closely at the binding properties of these peptides, the LOD for binding GI.1 and GII.17 were determined through a dilution series of VLPs directly coated to wells in the ELISA format.
The LOD values were defined as the lowest amount of VLPs that produced a statistically significant signal for detection as compared to wells containing no VLPs (P < 0.05). For detecting GI.1, the LODs were 8 ng and 16 ng for NV-O-R5-3 and NV-O-R5-6, respectively, while the LODs for binding GII.17 were 2 ng and 8 ng (Fig. 4) . Surprisingly, these peptides showed greater sensitivity for binding GII.17 than for GI.1, even though they had been originally selected for GI.1 binding during biopanning. Although NV-N-R5-1 previously showed a slightly lower GI.1 LOD at 1.56 ng, the 'YRSWXP' peptides possess the unique ability to bind GII.17 and with similarly strong sensitivity (Rogers et al., 2013) .
To understand why NV-O-R5-3 and NV-O-R5-6 have such broad specificity to both GI and GII norovirus genotypes, the region of the VP1 major capsid protein that they bind was mapped. Hypothetically, since the S-domain is the most conserved region across norovirus genogroups, whereas the P-domain is the most variable (Prasad et al., 1999) , these peptides would be expected to bind the S-domain in order to explain their broad binding specificity. This hypothesis was confirmed when both phage-displayed peptides elicited considerable binding signals against CT303, which is a GI.1 VLP lacking the P-domain and thus only exposing the S-domain (Fig. 5) (Bertolotti-Ciarlet et al., 2002) . Conversely, no signal was produced against the purified GI.1 P-domain. Statistically significant signals were shown for binding GI.1 VLPs by both phage-displayed peptides, though the average signal is less than that for S-domain, presumably since the S-domain is much less exposed to the surface of the full VLPs than in the CT303 VLPs that lack the P-domain. In contrast, phage-displayed peptide NV-N-R5-1 demonstrates specific binding to the P-domain of GI.1 and not the S-domain (CT303); this result explains this peptide's strong specificity for binding only genotype GI.1 and, because it binds a different site on the capsid, provides further support that it is distinct from the 'YRSWXP' motif peptides. The signal intensity for P-domain produced by NV-N-R5-1 is lower than for the full VLP possibly due In the first part, replicate peptides were removed so only unique sequences remained. These unique sequences (seqs) were next broken into 6-mer fragments and filtered based on their degree of identity to other fragments. Initially, fragments without at least three amino acids (#AA) in common with another fragment that did not originate from the same parent 12-mer were discarded, which resulted in the disposal of 78 'non-matching' fragments and returned 5249 (or 98.5% of the total number of 6-mer fragments) 'matching' peptides. The 'matching' peptides progressed to the 'data analysis' phase in which an alignment was produced using MAFFT software and visualized as a SeqLogo. (C) Processing the sequences with increasing stringency at the filtering step resulted in sequence logos that gradually revealed a consensus peptide motif that represented the filtered peptide fragments from the phage population after round four of biopanning (Materials and methods).
to the presence of unique binding surfaces available on the VLP where 180 copies of VP1 are arranged together in contrast to the isolated P-domain.
Peptides containing the consensus sequence bind GI.1 VLPs and virus in dot blots
Our previous studies have shown that NV-O-R5-3 and NV-O-R5-6 can detect VLPs directly coated to an ELISA plate, but suggested that detection of antibody-captured VLPs was not possible (Rogers et al., 2013) . In this study, we confirmed this characteristic by immobilizing either anti-norovirus polyclonal antibodies (Fig. S2) or monoclonal antibodies (data not shown) to an ELISA plate to capture a range of different VLPs. This was followed by detection with phage-displayed peptide NV-O-R5-3 or NV-O-R5-6, neither of which successfully detected any of the tested VLP genotypes (Fig.  S2) . The reverse sandwich format was also tested in which phagedisplayed peptides were immobilized directly onto an ELISA plate and used to capture VLPs. Polyclonal or monoclonal antibodies were used to detect the VLPs, though no detection signal was observed (data not shown). Thus, in order to demonstrate the utility of these new peptides in formats that readily translate into clinical diagnostics, dot blots were performed to evaluate the detection of norovirus VLPs and eventually virus in stool. In the dot blot format, both phage-displayed peptides successfully detected GI.1 VLPs diluted in PBS (Fig. 6) . Negative control M13KE phage showed no visible signal for binding VLPs at any concentration, while anti-NV polyclonal antibodies served as a positive control and showed strong binding signals down to 0.78 ng of VLPs. In dot blots where the phage-based peptides were used to detect GII.4 VLPs, signals were observed only at the highest VLP concentrations (Fig. S2) .
Next, both phage-displayed peptides were evaluated for their ability to detect VLPs specifically in 10% norovirus-negative stool without inhibition of binding or excessive background signal caused by components of the stool. Dot blots were performed similar to the above, except the VLPs were diluted in 10% norovirus-negative stool instead of PBS. The results demonstrated that both phagedisplayed peptides could specifically detect VLPs diluted in 10% norovirus-negative stool (Fig. 7) . Although the nitrocellulose membrane collects more background artifacts when stool is used to dilute VLPs compared to when using PBS, strong positive signals are observed at the VLP spots indicating successful and specific detection by the phages. The lowest concentration of VLPs that produced signals obviously visible to the eye was 12.5 ng with NV-O-R5-3 and 25 ng with NV-O-R5-6, which is similar to the result observed with VLPs diluted in PBS. The negative control phage, M13KE, showed only faint signals at the highest concentrations of VLPs (LOD 100 ng). At these high concentrations, the VLPs may be forming aggregates in the stool suspension resulting in non-specific binding by the phage and false positive signals. Overall, the results shown here indicate that the phage-displayed peptides detect VLPs specifically and do not bind other components found in the stool. Since the same concentration of stool suspension was used for all dilutions of VLPs, binding signals would have appeared at every VLP concentration if the phages were binding to components of the stool.
Finally, the two phage-displayed peptides were characterized for their ability to detect virus in clinical stool samples. Dot blots were performed in which stool samples that were previously confirmed either positive or negative for containing NV virions were serially diluted in PBS and immobilized directly onto nitrocellulose membranes. Virus was then detected with phage-displayed peptide and visualized through an anti-M13 phage HRP-conjugated antibody. Both peptides produced binding signals at concentrations down to 2.5% of NV-positive stool and did not show signal for binding the norovirus-negative stool that had been diluted in PBS and seeded at the same concentrations as the positive stool (Fig. 8) . Negative control phage M13KE did not show significant binding signals to the positive or negative stool samples. These results indicate that NV-O-R5-3 and NV-O-R5-6 phage-displayed peptides can be used effectively to detect virus in a clinically relevant diagnostic format.
Discussion
Overall, the combination of phage display technology and informatics sequence analysis in this study facilitated the discovery of a consensus peptide motif that demonstrates functional utility in binding noroviruses in clinically useful formats. The work shown here in identifying and then characterizing the motif in the context of two phage-displayed peptides-NV-O-R5-3 and NV-O-R5-6-provides significance in two ways. First, these particular phage-based reagents demonstrate diagnostic utility against multiple norovirus genotypes and can be applied effectively to detect virus in clinical stool samples. Second, the combined discovery methodologies used here can be applied to identify optimal consensus peptide sequences based on a given input peptide library to bind any target protein through biopanning and subsequent population-wide sequence analysis. Resulting consensus peptides with strong target-binding abilities may be translated to future diagnostic and therapeutic applications.
Phage-based reagents offer many advantages as diagnostic reagents
While the majority of existing diagnostic reagents for norovirus are antibodies, phage-based reagents offer many unique advantages in the context of product development and commercialization. First, protocols for amplifying large quantities of phages are cheap, simple and rapid to perform. Similar to antibodies, phages are easy to incorporate into existing assays in order to achieve fast results in clinically relevant formats. The peptides described here effectively detect a wide range of norovirus genotypes, which is useful as new variants emerge around the globe and a rapid tool that can detect many genotypes for point-of-care diagnosis is needed. Fig. 4 Determination of the binding sensitivity of phages encoding peptides with the 'YRSWXP' motif. Binding sensitivity for GI.1 (A) and GII.17 VLPs (B) are shown via the dose response of each NV-O-R5-3 and NV-O-R5-6 phage in a dilution series of VLPs starting at a maximum of 5 μg/mL. Signals are represented on the y-axis as the ratio of the signals produced at OD 450 by each phage and the M13KE negative control. LOD was defined as the lowest VLP concentration at which the phage produced a statistically significant signal compared to its signal at the baseline of zero ng/well of VLP. For GI.1, the LODs were 8 ng and 16 ng for NV-O-R5-3 and NV-O-R5-6, respectively, and 2 ng and 8 ng for GII.17.
Most notably, outbreaks caused by variants of GII.17 have gained momentum and are beginning to replace GII.4 as the dominant strain in circulation (De Graaf et al., 2015) . The number of sporadic GII.17 outbreaks has increased around the world in locations including Hong Kong (Chan et al., 2015) , Japan (Matsushima et al., 2015) , Italy (Medici et al., 2015) and one case in the United States with close genetic similarity to the outbreaks in Asia (Parra and Green, 2015) . In the winter of 2014-2015, GII.17 replaced GII.4 as the most predominant strain causing infections in Beijing, China (Gao et al., 2015) and is predicted to become a dominant strain worldwide in the near future (Dinu et al., 2016) . Public health community and surveillance programs need to be prepared for the potential increase in GII.17 prevalence by further evaluating and optimizing existing diagnostic assays. Seven existing immunochromatographic tests on the market in Europe (Théry et al., 2016) and four in Japan (Khamrin et al., 2015) were recently evaluated for their specificity for GII.17; while many of the tests can detect GII.17, they demonstrated very low sensitivity across the clinical stool samples tested, suggesting that optimization is needed for reliable detection of GII.17. The ability of our phage-displayed peptide, NV-O-R5-3, in particular, to effectively detect GI.1 and GII.17 with limits of detection reaching 8 ng and 2 ng, respectively, indicates that this Phage-displayed peptides containing the consensus peptide motif specifically bind VLPs in 10% stool suspensions. Phage-displayed peptides detected NV GI.1 VLPs at various concentrations when diluted in 10% stool suspensions that were confirmed previously to be negative for norovirus. Limits of detection (LODs) were determined as the lowest VLP concentration at which signal was visible and are highlighted by the red boxes in the figure.
Fig. 5
Phage-displayed peptides containing the 'YRSWXP' motif bind to the S-domain of VP1. Peptides containing the consensus peptide motif bind to GI.1 VLPs and even more specifically to the S-domain (represented by CT303). Phage-displayed peptide NV-N-R5-1 is shown for comparison and binds to GI.1 through the P-domain. Signals are reported on the y-axis as the ratio of the OD 450 produced by each phage-displayed peptide and the M13KE negative control. Significant positive signals are determined based on t-tests comparing signals displayed against the target VLP domain and BSA where P < 0.05. No significant binding was observed with the GI.1 P-domain by the 'YRSWXP' peptides.
phage would be highly useful to integrate into diagnostic formats to detect multiple genotypes and to improve the sensitivity for detecting GII.17. In contrast, reagents described previously, including NV-N-R5-1 and phage-displayed scFvs, have not demonstrated strong abilities to detect GII.17. While our two new peptide reagents demonstrated their strongest detection sensitivity with GII.17 among the genotypes tested, they also detect several other genotypes effectively, but with slightly weaker sensitivities (Fig. 3C) . Overall, improved diagnostic reagents that can detect emerging norovirus strains are needed to facilitate swift control and surveillance of future outbreaks, which suggests the potential utility of these new peptides .
Identification of the 'best' binding peptide from a peptide library
Although rounds of biopanning aim to enrich for the phage clones with the highest affinity for a target protein, studies have shown that other variables besides target-binding ability can influence which peptides survive through rounds of selection. Therefore, using biopanning as a selection method by itself can have several disadvantages, which are mitigated by complementation with computational methods in order to identify the 'best' binding peptide in the form of a population-wide consensus sequence.
One risk in biopanning is that phages can contain mutations that provide them with a growth advantage during the amplification phase between rounds of selection, thus inflating the frequency of the displayed peptide in the phage population (Brammer et al., 2008; Vodnik et al., 2011; Matochko et al., 2014; Nguyen et al., 2014) . One particular mutation in the Shine-Dalgarno sequence of gene II has been identified and linked directly to phage propagation advantages (Brammer et al., 2008; Nguyen et al., 2014) . Consequently, the most frequently occurring peptides might not necessarily be the best binders, and low frequency peptides may actually be good binders. Computational analysis of the entire population of peptide sequences without bias for high frequency peptides overcomes this issue.
Second, peptides that result from biopanning may bind to targetunrelated components of the selection system such as plastic or milk. Computational analysis of the entire population of peptides can help to eliminate these peptides when they occur by chance and are not real target binders. A scan of SAROTUP, a web-based database of known target-unrelated peptides, provides one resource to indicate that candidate or consensus peptides are not target-nonspecific (Huang et al., 2010) . Based on the most recent contents of the SAROTUP database, none of the peptides characterized here contain motifs related to known off-target binders.
Finally, while the original phage display library used for biopanning contains one billion randomized peptides, it covers less than one millionth of the possible 12-mer sequences (BioLabs). This suggests that the 'best' binding peptide among all possible peptides may not exist in the library and that lead peptides identified by biopanning could be optimized to develop improved binders. Using computational methods to identify a consensus motif provides one opportunity for peptide optimization by creating the possibility of discovering a sequence that doesn't appear exactly in the selected peptide population, thus expanding the potential coverage of the library originally used.
In summary, the work reported here characterizes two phagedisplayed peptide reagents that can be used for clinical diagnostic tests to detect both GI and GII noroviruses. It also presents a useful combination of methods that can facilitate the identification of consensus peptide motifs that bind alternate protein targets in the future. produce binding signals against virus contained in clinical stool collected previously from volunteers in a GI.1 challenge study. Stool was diluted to various concentrations in suspension with PBS. Positive signals appeared at the highest three stool concentrations (2.5-10%) with both phage-displayed peptides and are boxed in red. Neither peptide bound to negative stool (-neg) diluted to the same concentrations, and M13KE showed no positive signals for binding any stool suspensions.
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